Source comparison
Tesamorelin Peptide Combination: Protocol Comparison
Tesamorelin + GHRP-2 Dual-pathway GH release (GHRH + ghrelin) GHRP-2 100–300 mcg / Tesamorelin 1–2 mg 2–3× peak GH vs monotherapy, enhanced lipolysis Most-studied combination with strong synergy. Safe when dosed correctly Tesamorelin + Ipamorelin Selective GH
This comparison does not assign a generated winner or score.
- Tesamorelin + GHRP-2
- Dual-pathway GH release (GHRH + ghrelin)
- GHRP-2 100–300 mcg / Tesamorelin 1–2 mg
- 2–3× peak GH vs monotherapy, enhanced lipolysis
- Most-studied combination with strong synergy. Safe when dosed correctly
- Tesamorelin + Ipamorelin
- Selective GH amplification without appetite/cortisol spikes
- Ipamorelin 200–300 mcg / Tesamorelin 1–2 mg
- Clean GH pulse, minimal sides, moderate fat loss
- Best option for users prioritizing side-effect profile over maximum GH output
- Tesamorelin + CJC-1295 (no DAC)
- Overlapping GHRH pathway
- Not recommended. Receptor competition
- No synergy, wasted dosage
- Use one or the other. Never both
- Tesamorelin + MK-677
- Chronic ghrelin activation + pulsatile GHRH
- MK-677 12.5–25 mg daily / Tesamorelin 1–2 mg
- Blunted acute GH response from receptor desensitization
- Avoid. MK-677's chronic activation reduces tesamorelin efficacy
- Tesamorelin + BPC-157
- Independent pathways (GH vs tissue repair signaling)
- BPC-157 250–500 mcg / Tesamorelin 1–2 mg
- Complementary benefits with no interaction
- Safe to combine. Mechanisms don't overlap